Document is current
Any future updates will be listed below
-
Authors
Janakiram, Murali
Liu, Lawrence https://orcid.org/0000-0001-8559-7739
Goldsmith, Scott
Borogovac, Azra
Lee, Sarah
Nathwani, Nitya
Rosenzweig, Michael
Sahebi, Firoozeh
Htut, Myo
- License Information
-
More Information
Article History
Received: 28 April 2025
Revised: 20 June 2025
Accepted: 28 July 2025
First Online: 11 August 2025
Competing interests
: MJ: Consulting: Janssen, BMS, Legend. Research: Janssen, BMS, Fate Therapeutics. LWL: Received honorarium from MJH Life Sciences, CAHON, and Medscape. Stocks in Roche and Pfizer. Support of attending meetings for DAVA Oncology. SG: consultancy: Bristol-Myers Squibb, Janssen, Sanofi; research funding: Bristol-Myers Squibb, Ipsen; speaker bureau: Adaptive Biotechnologies, Janssen. AB: Honorarium: Prime Education. Consultant: Janssen. SL: Consultancy: Abbvie, Cellectar, Janssen; Research Funding: BMS. NN: No financial competing interests. MR: Grants from J&J and Pfizer; Speakers Bureau for Janssen and BMS; support of attending meetings for DAVA Oncology; patent vis City of Hope. FS: No financial competing interests. MH: Consulting or Advisory Role: Millennium. Research Funding: Judy and Bernard Briskin Center for Myeloma (Inst), BMS (Inst). Travel, Accommodations, Expenses: Millennium.
